Sunvozertinib (Zegfrovy) for NSCLC
Sunvozertinib (Zegfrovy – Dizal), an oral kinase inhibitor, has received accelerated approval from the FDA for treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations who had disease progression on or after platinum-based chemotherapy.
Publication Details
- Journal
- The medical letter on drugs and therapeutics/The medical letter
- Published
- 2025-09-04
- DOI
- https://doi.org/10.58347/tml.2025.1737f
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00